Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Peyrot

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Diabetes Care|March 23, 2017
Richard R. Rubin, PhD: An Ambassador for Behavioral Science in DiabetesMark Peyrot
Pediatric Diabetes|November 26, 2009
The DAWN Youth WebTalk Study: methods, findings, and implicationsMark Peyrot,
Diabetes Care|September 30, 2003
Depression: a quiet killer by any nameMark Peyrot
Diabetes Care|September 29, 2004
Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategiesRichard R Rubin, Mark Peyrot
Journal of Diabetes Science and Technology|February 11, 2010
Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pumpRichard R Rubin, Mark Peyrot
Current Medical Research and Opinion|July 17, 2008
Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitusMark Peyrot, Richard R Rubin
Current Medical Research and Opinion|July 13, 2007
Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapyRichard R Rubin, Mark Peyrot
Pediatric Endocrinology Reviews : PER|September 30, 2010
Patient-reported outcomes and diabetes technology: a systematic review of the literatureRichard R Rubin, Mark Peyrot
Diabetes Technology & Therapeutics|January 20, 2010
Effect of technosphere inhaled insulin on quality of life and treatment satisfactionMark Peyrot, Richard R Rubin
Diabetes Technology & Therapeutics|December 3, 2011
Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trialRichard R Rubin, Mark Peyrot,
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Diabetes Care|March 23, 2017
Richard R. Rubin, PhD: An Ambassador for Behavioral Science in DiabetesMark Peyrot
Pediatric Diabetes|November 26, 2009
The DAWN Youth WebTalk Study: methods, findings, and implicationsMark Peyrot,
Diabetes Care|September 30, 2003
Depression: a quiet killer by any nameMark Peyrot
Diabetes Care|September 29, 2004
Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategiesRichard R Rubin, Mark Peyrot
Journal of Diabetes Science and Technology|February 11, 2010
Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pumpRichard R Rubin, Mark Peyrot
Current Medical Research and Opinion|July 17, 2008
Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitusMark Peyrot, Richard R Rubin
Current Medical Research and Opinion|July 13, 2007
Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapyRichard R Rubin, Mark Peyrot
Pediatric Endocrinology Reviews : PER|September 30, 2010
Patient-reported outcomes and diabetes technology: a systematic review of the literatureRichard R Rubin, Mark Peyrot
Diabetes Technology & Therapeutics|January 20, 2010
Effect of technosphere inhaled insulin on quality of life and treatment satisfactionMark Peyrot, Richard R Rubin
Diabetes Technology & Therapeutics|December 3, 2011
Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trialRichard R Rubin, Mark Peyrot,
Pageof 13